The study will evaluate Signal's MyPRS test for stratifying patients at risk of developing symptomatic multiple myeloma.
The genetic test determines risk levels and prognosis for patients with multiple myeloma based on the SKY92 gene signature.
The deals with Stratose, USA Managed Care Organization, and Evolutions Health Systems provides covered access to the test to more than 21 million patients.
NIH researchers have uncovered a blood-based microRNA signature that may be able to tell which patients with precursor disease may progress to myeloma.
The partners will run several studies to validate the use of the MyPRS test in informing disease management in patients with multiple myeloma and its precursors.
As part of the Myeloma XI trial, a UK-led team used exome sequencing on 463 individuals with myeloma to look for mutations related to survival patterns.
The company's revenues fell as test orders from its primary customer dropped 22 percent, a trend it said is expected to continue.
In PNAS this week: optical mapping study of multiple myeloma, role for miR-204 in form of retinal dystrophy, and more.
By combining optical mapping with DNA sequencing, University of Wisconsin-Madison researchers examined structural variation that occurs in multiple myeloma tumors.
The partners will compare Adaptive Bio's clonoSeq MRD test with flow cytometry for accuracy and reliability in monitoring MRD in multiple myeloma patients.
The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.
There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.
The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.
In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.